ConvaTec Group H2 Earnings Call Highlights

Infusion Care: Organic growth was 12.5%. Ryder said demand in diabetes remained strong as automated insulin delivery penetration increased, while non-diabetes growth was led by infusion sets for AbbVie’s Parkinson’s disease therapy. Other therapies rose to 15% of infusion care revenue, up from about 10% in 2024.Continence Care: Organic growth was 6.6%, driven by higher U.S. volumes and a growing mix of ConvaTec-branded products. Hydrophilic products were again more than 60% of the category’s revenue, and in ...